Introducing HrC Genomics
- Simple Pan-Cancer Blood Test
- 93% Accuracy/Sensitivity
- Validated for 60+ Cancers
- Detects 'Absence' of Cancer
- Tracks Signatures at Stage 0
- Edison Gold Award Winners 2025
What is HrC Genomics?
HrC is a simple risk assessment to facilitate early detection of cancer.
Through HrC we can:
- Identify that there is “no risk” of cancer presence (which also suggests a negligible risk of developing cancer within the following one year).
- Assess existing risk of cancer presence which can vary from negligible, low, moderate, to high.
Absence of Cancer
A “no risk” score on the HrC test indicates that the molecular markers are within the range of a healthy individual who is cancer-free, with 93% accuracy/sensitivity.
Who Can Take the Test?
Asymptomatic Patients
Cancer Screening
- Evaluate current risk of cancer presence.
- Detect early molecular or cellular changes associated with pre-symptomatic cancer development.
- Provide early molecular indicators for clinical correlation.
- Differentiate benign or malignant tumour condition from healthy population.
- Identify precancerous conditions amenable to preventive treatment. Early-stage interventions can improve therapeutic response.
- Contribute to better health economics through earlier disease detection.
- Identify high-risk population requiring close and periodic monitoring.
- Enable large-scale, population-level health surveillance.
Suitable For:
- Asymptomatic individuals seeking preventive assessment.
- Symptomatic individuals wanting to assess underlying triggers, if any.
- Individuals with a known family history of cancer.
Expected Outcomes (HrC Score Interpretation)
HrC Score | Interpretation |
≤ 2 | Negligible risk of cancer presence |
2–6 | Low or indeterminate risk |
6–10 | Moderate risk |
> 10 | High risk of active or likely developing malignancy |
Elevated scores (6–10 or >10) indicate potentially increased oncogenic activity requiring close monitoring and/or clinical evaluation.
Recommended Frequency
Repeat every 3 to 12 months depending on the score and clinical history.
Clinical Advice
Interpret results alongside radiological findings, histopathology, blood investigations, and relevant tumour markers.
Conclusion
This screening empowers clinicians and individuals with actionable information to facilitate early intervention and improve clinical outcomes.
Cancer Patients
Monitoring Responsiveness to Treatment
- Assess therapeutic response at pre-, during-, and post-treatment stages.
- Monitor individualised treatment effectiveness.
- Enhance survival outcomes through early recognition of treatment resistance or response.
Suitable For:
- Patients currently receiving active therapy for cancer.
HrC Genomics for Cancer Patients
For existing cancer patients, HrC Genomics can become an adjuvant to existing radiological tests that are widespread today. It can significantly reduce (though not eliminate) need for performing invasive tissue biopsies, which oftentimes cause spillage, and can also accelerate metastasis. The non-invasiveness and safety of HrC Genomics lends itself to being a quick test with which one can monitor responsiveness to treatment protocols. Additionally, it can reliably ascertain whether the cancer is in progression, regression, or in complete remission.
Expected Outcomes (HrC Score Interpretation)
HrC Score | Interpretation |
≤ 2 | Consistent with continued treatment response, especially if multi-timepoint scores show a steadily non-adverse trend. |
> 2 | Requires individualised clinical evaluation and multi-timepoint scores to assess a progressive adverse or non-adverse trend. |
Recommended Frequency
Two-timepoint testing is recommended:
- Baseline sample preferably prior to therapy initiation. However, during treatment samples can also be collected for establishing baseline score. NB: Sample should be collected prior to the next treatment.
- Follow-up approximately 3 to 4 weeks after treatment completion to capture stable biological signatures related to treatment response and not the acute effects of drug treatment. For in-treatment sampling, the second sample should be collected 3 to 4 weeks post-therapy.
Clinical Advice
Results should always be correlated with radiological scans, histopathology, blood tests, or tumour markers.
Conclusion
Regular monitoring facilitates timely modification of therapy, optimising treatment success and improving patient prognosis.
Cancer Survivors
Confirming Remission
Why perform the HrC Genomics Test post-remission?
- Monitor remission status following completion of therapy.
- Detect early recurrence and improve post-remission survival rates.
- Identify secondary malignancies or metastatic reactivation.
- Support long-term health tracking and enhance quality of life.
Suitable For:
- Cancer survivors who have been disease-free for at least six months after treatment completion.
HrC Genomics for Cancer Survivors
Cancer is known to reappear in cancer survivors even after 10-15 years of being cancer-free. Recurrence of cancer is immensely dangerous as it is usually detected in late stages only, post metastasis. In such cases, Oncologists are aware that chances of survival are poor. If taken as a routine annual surveillance test, HrC Genomics can become the most effective way to monitor potential relapse.
Expected Outcomes (HrC Score Interpretation)
HrC Score | Interpretation |
≤ 2 | Consistent with continued treatment response, especially if multi-timepoint scores show a steadily non-adverse trend. |
> 2 | Requires individualised clinical evaluation and multi-timepoint scores to assess a progressive adverse or non-adverse trend. |
Recommended Frequency
Two-timepoint testing is recommended:
- Baseline sample preferably prior to therapy initiation. However, during treatment samples can also be collected for establishing baseline score. NB: Sample should be collected prior to the next treatment.
- Follow-up approximately 3 to 4 weeks after treatment completion to capture stable biological signatures related to treatment response and not the acute effects of drug treatment. For in-treatment sampling, the second sample should be collected 3 to 4 weeks post-therapy.
Clinical Advice
Results should always be correlated with radiological scans, histopathology, blood tests, or tumour markers.
Conclusion
Regular monitoring facilitates timely modification of therapy, optimising treatment success and improving patient prognosis.
Eligibility Criteria
HrC Genomics is available to individuals aged 18 and over.
However, individuals who meet the following criteria are not eligible to take the test:
- Pregnant
- Postpartum
- HIV Positive/Seropositive
Individuals who have had hormone therapy and/or gender realignment surgery are eligible to take the test. However, they should be aware that hormone therapy and/or gender realignment surgery can impact test results, resulting in reduced accuracy.
In such instances, individuals will be asked to confirm their understanding and acceptance of the same, prior to taking the test.
Patient Information & Consent Form
Each and every person taking an HrC Genomics Test is required to complete a Patient Information & Consent Form (PIF).
The PIF is used to gather an individual’s personal and medical information. It is also where an individual will confirm that they:
- Meet the required eligibility criteria
- Understand and Accept conditions that may impact the test results
- Consent to their sample being processed by Tzar Labs